Skip to main content

Advertisement

Springer Nature Link
Log in

Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major

  • Original Article
  • Published:
Journal of Parasitic Diseases Aims and scope Submit manuscript

Abstract

Leishmaniasis is a major infectious disease caused by protozoan parasites of the genus Leishmania. Despite of many efforts toward vaccine against Leishmania no effective vaccine has been approved yet. DNA vaccines can generate more powerful and broad immune responses than conventional vaccines. In order to increase immunity, the DNA vaccine has been supplemented with adjuvant. In this study a new nano-vaccine containing TSA recombinant plasmid and poly(methylmethacrylate) nanoparticles (act as adjuvant) was designed and its immunogenicity tested on BALB/c mouse. After three intramuscular injection of nano-vaccine (100 μg), the recombinant TSA protein (20 μg) was injected subcutaneously. Finally as a challenge animals were infected by Leishmania major. After the last injection of nano-vaccine, after protein booster injection, and also after challenge, cellular immune and antibody responses were evaluated by ELISA method. The findings of this study showed the new nano-vaccine was capable of induction both cytokines secretion and specific antibody responses, but predominant Th1 immune response characterized by IFN-γ production compared to control groups. Moreover, results revealed that nano-vaccine was effective in reducing parasite burden in the spleen of Leishmania major-infected BALB/c mice. Base on results, current candidate vaccine has potency for further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  • Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K (2004) A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 22:1631–1639

    Article  CAS  PubMed  Google Scholar 

  • Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C (2009) DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice. Vaccine 27:99–106

    Article  CAS  PubMed  Google Scholar 

  • Badiee A, Heravi Shargh V, Khamesipour A, Jaafari MR (2013) Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine 31:735–749

    Article  CAS  PubMed  Google Scholar 

  • Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J (2005) Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immunol 174:6292–6298

    Article  CAS  PubMed  Google Scholar 

  • Buffet PA, Sulahian A, Garin YJ, Nassar N, Derouin F (1995) Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39:2167–2168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Campos-Neto A (2005) What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Brazilian J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al] 38:979–984

  • Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA et al (2001) Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69:4103–4108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG (2002) Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun 70:2828–2836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Crowther JR (2013) ELISA. Theory and practice. Methods Mol Biol 1995(42):1–218

    Google Scholar 

  • Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S (2011) Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomed 6:835–842

    CAS  Google Scholar 

  • Fatemeh G, Fatemeh T, Zohreh S, Abdolhosein D, Mohammad Zahir H, Mehdi M (2012) Cloning of a recombinant plasmid encoding thiol-specific antioxidant antigen (TSA) gene of Leishmania major and expression in the Chinese hamster ovary cell line. Malays J Med Sci 19:15–19

    PubMed  PubMed Central  Google Scholar 

  • Gradoni L (2001) An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 100:87–103

    Article  CAS  PubMed  Google Scholar 

  • Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14:229–243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ivory C, Chadee K (2004) DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2:17

    Article  PubMed  PubMed Central  Google Scholar 

  • Kreuter J (1995) Nanoparticles as adjuvants for vaccines. Pharm Biotechnol 6:463–472

    Article  CAS  PubMed  Google Scholar 

  • Kreuter J (1996) Nanoparticles and microparticles for drug and vaccine delivery. J Anat 189(Pt 3):503–505

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kreuter J, Mauler R, Gruschkau H, Speiser PP (1976) The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp Cell Biol 44:12–19

    CAS  PubMed  Google Scholar 

  • Kwissa M, Lindblad EB, Schirmbeck R, Reimann J (2003) Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J Mol Med 81:502–510

    Article  CAS  PubMed  Google Scholar 

  • Lou PJ, Cheng WF, Chung YC, Cheng CY, Chiu LH, Young TH (2009) PMMA particle-mediated DNA vaccine for cervical cancer. J Biomed Mater Res Part A 88:849–857

    Article  Google Scholar 

  • Mauel J (2002) Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2:201–226

    Article  CAS  PubMed  Google Scholar 

  • Mendez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YA et al (2001) The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166:5122–5128

    Article  CAS  PubMed  Google Scholar 

  • Mendez S, Belkaid Y, Seder RA, Sacks D (2002) Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702–3708

    Article  CAS  PubMed  Google Scholar 

  • Miyazaki J, Aihara H (2002) Gene transfer into muscle by electroporation in vivo. Methods Mol Med 69:49–62

    CAS  PubMed  Google Scholar 

  • Monnerat S, Martinez-Calvillo S, Worthey E, Myler PJ, Stuart KD, Fasel N (2004) Genomic organization and gene expression in a chromosomal region of Leishmania major. Mol Biochem Parasitol 134:233–243

    Article  CAS  PubMed  Google Scholar 

  • Mutiso JM, Macharia JC, Gicheru MM (2010) A review of adjuvants for Leishmania vaccine candidates. J Biomed Res 24:16–25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’Hagan DT (2000) Methods in molecular medicine, vaccine adjuvants: preparation methods and research protocols. Humana Press, Totowa

    Book  Google Scholar 

  • Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N (2001) Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol 113:35–43

    Article  CAS  PubMed  Google Scholar 

  • Rafati S, Zahedifard F, Nazgouee F (2006a) Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24:2169–2175

    Article  CAS  PubMed  Google Scholar 

  • Rafati S, Ghaemimanesh F, Zahedifard F (2006b) Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice. Vaccine 24:3290–3297

    Article  CAS  PubMed  Google Scholar 

  • Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC (2006) Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24:1928–1940

    Article  CAS  PubMed  Google Scholar 

  • Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, New York

    Google Scholar 

  • Sasaki S, Takeshita F, Xin KQ, Ishii N, Okuda K (2003) Adjuvant formulations and delivery systems for DNA vaccines. Methods 31:243–254

    Article  CAS  PubMed  Google Scholar 

  • Stieneker F, Kersten G, van Bloois L, Crommelin DJ, Hem SL, Lower J et al (1995) Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 13:45–53

    Article  CAS  PubMed  Google Scholar 

  • Tabatabaie F, Ghaffarifar F, Sharifi Z, Dalimi A, Zavaran Hoseini A (2007) Cloning and sequencing of Leishmania major thiol-specific antioxidant antigen (TSA) gene. Iranian J Parasitol 2:30–41

    CAS  Google Scholar 

  • Tewary P, Jain M, Sahani MH, Saxena S, Madhubala R (2005) A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 191:2130–2137

    Article  CAS  PubMed  Google Scholar 

  • Voltan R, Castaldello A, Brocca-Cofano E, Altavilla G, Caputo A, Laus M et al (2007) Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res 24:1870–1882

    Article  CAS  PubMed  Google Scholar 

  • Webb JR, Kaufmann D, Campos-Neto A, Reed SG (1996) Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 157:5034–5041

    CAS  PubMed  Google Scholar 

  • Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R et al (1998) Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66:3279–3289

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S (2004) Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine 22:1930–1940

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Microbiology Department, Science & Research Branch, Islamic Azad University, Tehran, Iran

    Somayeh Zarrati

  2. Virology Department, Pasteur Institute of Iran, Tehran, Iran

    Mehdi Mahdavi

  3. Department of Parasitology and Mycology, Faculty of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran

    Fatemeh Tabatabaie

Authors
  1. Somayeh Zarrati
    View author publications

    Search author on:PubMed Google Scholar

  2. Mehdi Mahdavi
    View author publications

    Search author on:PubMed Google Scholar

  3. Fatemeh Tabatabaie
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Fatemeh Tabatabaie.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zarrati, S., Mahdavi, M. & Tabatabaie, F. Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major . J Parasit Dis 40, 427–435 (2016). https://doi.org/10.1007/s12639-014-0521-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12639-014-0521-8

Keywords

Profiles

  1. Mehdi Mahdavi View author profile